BioAdvance

Tolerance Bio is a biopharmaceutical company focused on manipulating immune tolerance via the thymus to address various immune-mediated diseases thymus.

ViTToria Biotherapeutics specializes in developing gene-edited cell therapies, focusing on next-generation T-cell therapeutics that aim to address significant unmet medical needs. The company’s proprietary Senza5 Technology enhances the efficacy, safety, and utility of these cell-based treatments in preclinical settings. By improving dosing requirements, simplifying preconditioning regimens, minimizing manufacturing failures, and reducing the time from production to patient administration, ViTToria Biotherapeutics enables healthcare providers to achieve better patient outcomes. The innovative approach of the company positions it as a leader in the evolving field of cell therapies.

KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is to develop the first-in-class immuno- and targeted therapies to drive cures in advanced cancers KayoThera was founded in 2019 and is headquartered in Princeton, New Jersey.

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Senzo is focused on developing innovative in vitro diagnostics technology aimed at providing accurate and accessible testing solutions. The company has created a rapid blood diagnostic platform that allows for the simultaneous execution of common laboratory tests on a portable device. This technology enables mobile, point-of-care, and self-testing products, empowering individuals to manage their healthcare information directly. By offering these cost-effective and efficient testing options, Senzo aims to enhance the quality of life for users through improved access to essential health information.

Innervace is a regenerative therapy company based in Philadelphia, Pennsylvania, focused on developing implantable tissue-engineered brain pathways to address neurodegenerative disorders. The company specializes in creating anatomically inspired living scaffolds designed for brain pathway reconstruction. Its lead clinical product is a tissue-engineered nigrostriatal pathway, which aims to replicate the lost pathway in patients with Parkinson's disease. By concentrating on the reconstruction of brain pathways rather than merely alleviating symptoms temporarily, Innervace offers innovative solutions that aim to improve the quality of life for individuals affected by these conditions. Established in 2018, the company is dedicated to advancing its products from development to commercialization.

Senzo is focused on developing innovative in vitro diagnostics technology aimed at providing accurate and accessible testing solutions. The company has created a rapid blood diagnostic platform that allows for the simultaneous execution of common laboratory tests on a portable device. This technology enables mobile, point-of-care, and self-testing products, empowering individuals to manage their healthcare information directly. By offering these cost-effective and efficient testing options, Senzo aims to enhance the quality of life for users through improved access to essential health information.

Halo Labs is a life science instrumentation company based in Burlingame, California, that specializes in developing tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technology. Its offerings include tools for biologics-developability assessment, formulation development, small molecule solubility, and AAV analytics. Founded in 2011, Halo Labs has gained recognition in the industry, receiving support from notable investors and partners such as BioAdvance and the National Science Foundation. The company aims to provide researchers with accurate insights into the stability and quality of biological drugs.

KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is to develop the first-in-class immuno- and targeted therapies to drive cures in advanced cancers KayoThera was founded in 2019 and is headquartered in Princeton, New Jersey.

Phrase Health help hospitals monitor and analyze the information they provide to doctors and nurses at the point of care.

Wellsheet is a technology company that enhances electronic health record (EHR) systems by organizing clinical information using machine learning. Its platform prioritizes the most relevant information for healthcare providers, facilitating quicker clinical insights and improving patient care. By integrating seamlessly with existing EHR systems, Wellsheet enables physicians to access contextualized data, which enhances efficiency and accuracy during patient interactions. The company has demonstrated its effectiveness in a large health system in New Jersey and has established partnerships with major EHR vendors to distribute its services through a software-as-a-service model. This approach allows healthcare providers to implement improvements without overhauling their current systems.

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Halo Labs is a life science instrumentation company based in Burlingame, California, that specializes in developing tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technology. Its offerings include tools for biologics-developability assessment, formulation development, small molecule solubility, and AAV analytics. Founded in 2011, Halo Labs has gained recognition in the industry, receiving support from notable investors and partners such as BioAdvance and the National Science Foundation. The company aims to provide researchers with accurate insights into the stability and quality of biological drugs.

Ride Health LLC is a New York-based company that offers a software-as-a-service platform designed to improve patient access to medical appointments by managing transportation logistics. Founded in 2016, the platform enables healthcare providers to schedule, request, and pay for rides on behalf of patients, addressing transportation barriers that can hinder access to care. It allows coordinators to arrange rides in advance or on-demand, provides real-time updates and reminders to patients, and offers insights into transportation costs and usage. By partnering with healthcare organizations and transportation providers, Ride Health enhances enterprise transportation programs and supports at-risk populations, ensuring that patient needs and preferences are prioritized. This approach aims to improve efficiencies, reduce costs, and ultimately foster better healthcare outcomes.

Pillo Health specializes in providing tools for caregivers and health organizations to enhance care for individuals living at home. Central to its offerings is an intelligent healthcare assistant, Pillo, which manages medications and delivers health and wellness information directly to patients. The platform facilitates the proactive delivery of digital care plans and connects patients with care teams through notifications and video calls. Additionally, Pillo Health offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further adapting it to meet specific health management needs. Overall, the company aims to improve the longevity and quality of life for patients by ensuring they adhere to their care plans and maintain connections with healthcare providers.

Phrase Health help hospitals monitor and analyze the information they provide to doctors and nurses at the point of care.

Halo Labs is a life science instrumentation company based in Burlingame, California, that specializes in developing tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technology. Its offerings include tools for biologics-developability assessment, formulation development, small molecule solubility, and AAV analytics. Founded in 2011, Halo Labs has gained recognition in the industry, receiving support from notable investors and partners such as BioAdvance and the National Science Foundation. The company aims to provide researchers with accurate insights into the stability and quality of biological drugs.

Bainbridge Health provides hospital systems with a clinical intelligence and data analytics platform to improve medication safety. It provides hospital safety professionals with an infusion pump management software solution to better manage pump data and enhance patient safety. Bainbridge Health also offers a clinician-focused infusion pump management system known as InfusionWare that enables clinicians to manage infusion data in one centralized location.

Opsidio is a biotechnology company based in Bryn Mawr, Pennsylvania, founded in 2012. The company specializes in developing monoclonal antibodies aimed at treating fibrotic and remodeling diseases, as well as allergic conditions. Opsidio's innovative antibodies specifically target a unique form of the Stem Cell Factor, which plays a crucial role in the cascade of profibrotic cytokines. This targeted approach enables healthcare providers to address various serious conditions, including idiopathic pulmonary fibrosis, chronic kidney disease, systemic sclerosis, and severe asthma, ultimately improving treatment options for affected patients.

Oncora Medical, Inc. is a digital health company focused on enhancing radiation oncology through an innovative analytics platform. Founded in 2014 and based in Philadelphia, Pennsylvania, the company provides tools that facilitate the integration of clinical data from electronic medical records, treatment planning software, and oncology information systems. This allows radiation oncologists to make personalized treatment recommendations based on historical data and predictive analytics. The platform also employs machine learning algorithms to analyze patient outcomes, enabling oncologists to improve cancer care and optimize treatment strategies. By leveraging real-world data, Oncora Medical aims to support better healthcare decisions and ultimately enhance patient outcomes in radiation oncology.

Wellsheet is a technology company that enhances electronic health record (EHR) systems by organizing clinical information using machine learning. Its platform prioritizes the most relevant information for healthcare providers, facilitating quicker clinical insights and improving patient care. By integrating seamlessly with existing EHR systems, Wellsheet enables physicians to access contextualized data, which enhances efficiency and accuracy during patient interactions. The company has demonstrated its effectiveness in a large health system in New Jersey and has established partnerships with major EHR vendors to distribute its services through a software-as-a-service model. This approach allows healthcare providers to implement improvements without overhauling their current systems.

Olive Devices is an assistive device company developing smart glasses to improve communication for deaf and hard of hearing persons.

CytoVas LLC is a life science company based in Philadelphia, Pennsylvania, that specializes in developing an innovative informatics platform, CLOUD CYTOMICS. This platform is designed to analyze flow cytometry data, providing clinicians and drug developers with actionable insights on novel cellular markers related to disease progression and individual treatment responses. By automating data collection and interpretation, CLOUD CYTOMICS enables rapid identification of cellular biomarkers, facilitating critical decision-making in the development of targeted therapies. The technology is applicable across various therapeutic areas, including cardiovascular disease, type 2 diabetes, Alzheimer’s, and more. Founded by experts in computational biology and flow cytometry from the University of Pennsylvania, CytoVas is supported by significant investments from organizations such as the American Heart Association and the National Institutes of Health, as well as a partnership with Becton Dickinson Biosciences. The company continues to explore the potential of its platform in diverse medical research fields.

WellTrackONE is a population health management company that offers an end-to-end solution to physician offices, ACOs, integrated delivery networks, hospitals, and other physician networks that helps them administer the Medicare Annual Wellness Visit to all their Medicare patients. The company provides clinical risk management services used to offer a comprehensive baseline report for detailing modifiable risk factors, preventative goals, and measurable data. It was founded in 2012 and headquartered in Hilton Head Island, South Carolina.

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Genome Profiling, LLC (www.genprollc.com) is at the forefront of this rapidly emerging market with the first epigenetic biomarker discovery platform that combines a proprietary pre-NGS gDNA preparation kit matched to powerful NGS data analytics algorithms that plug-n-play into standard NGS workflows and enable one NGS run to deliver data for both genomic variant call analyses data AND epigenetic data.

HueDx is a developer of point-of-care diagnostic tests aimed at enhancing patient care. The company utilizes innovative paper- or wax-based microfluidics technology to deliver rapid, quantitative assay-based tests that provide quick results across a range of applications. By eliminating the need for physical devices and software, HueDx's platform streamlines the test development and launch process, making diagnostics more accessible and cost-effective. This approach not only improves transparency for clinicians but also facilitates immediate patient results, ultimately contributing to a more efficient healthcare delivery system.

TalexMedical is the proud producer of Infantear – a revolutionary Class I medical device for the treatment of external ear deformities in newborns. InfantEar is a simple, yet elegant, nonsurgical ear molding system, applied in the outpatient setting, replacing the costly, labor intensive surgical ear procedure. The unique, fully customizable device is made of soft materials for increased comfort. Targeted primarily to pediatricians, who can recognize and treat the ear anomaly with one two-week treatment applied to a patient in the first three weeks of life, avoiding the delayed and costly external referral with specialists. This helps us to achieve the Triple Aim of Healthcare – improved results, increased patient satisfaction and decreased cost.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. Founded in 2010 and based in Malvern, Pennsylvania, the company specializes in developing antibacterial drugs to combat resistant infections commonly encountered in hospital and community settings, such as those caused by MRSA, Pseudomonas spp., and Salmonella spp. Venatorx employs innovative chemical approaches to create treatments that exhibit selective and potent activity against various resistant bacterial strains, thereby providing healthcare professionals with broader treatment options to address significant unmet medical needs.

Ride Health LLC is a New York-based company that offers a software-as-a-service platform designed to improve patient access to medical appointments by managing transportation logistics. Founded in 2016, the platform enables healthcare providers to schedule, request, and pay for rides on behalf of patients, addressing transportation barriers that can hinder access to care. It allows coordinators to arrange rides in advance or on-demand, provides real-time updates and reminders to patients, and offers insights into transportation costs and usage. By partnering with healthcare organizations and transportation providers, Ride Health enhances enterprise transportation programs and supports at-risk populations, ensuring that patient needs and preferences are prioritized. This approach aims to improve efficiencies, reduce costs, and ultimately foster better healthcare outcomes.

Pillo Health specializes in providing tools for caregivers and health organizations to enhance care for individuals living at home. Central to its offerings is an intelligent healthcare assistant, Pillo, which manages medications and delivers health and wellness information directly to patients. The platform facilitates the proactive delivery of digital care plans and connects patients with care teams through notifications and video calls. Additionally, Pillo Health offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further adapting it to meet specific health management needs. Overall, the company aims to improve the longevity and quality of life for patients by ensuring they adhere to their care plans and maintain connections with healthcare providers.

Keriton LLC is a provider of a pumped breast milk management system specifically designed for neonatal intensive care units (NICUs). Based in Philadelphia, Pennsylvania, the company offers a comprehensive platform that enhances patient safety and streamlines nursing workflows. This system enables healthcare professionals to track milk-bottle inventory, manage feeding orders, and handle first-in-first-out (FIFO) bottle flow, including notifications for expiry dates and misfeed alerts. The platform also facilitates real-time insights into lactating mothers' milk production patterns and includes a media-sharing feature for nurses to communicate with mothers by sharing photos and videos of their babies. With a track record of managing over 1.5 million feeds and preventing nearly 30,000 errors, Keriton's solution aims to improve health outcomes and reduce the cognitive burden on hospital staff. Since its incorporation in 2016, Keriton has been deployed in numerous larger enterprise health systems, demonstrating its effectiveness in enhancing the care provided to infants in NICUs.

Mebias Discovery, LLC is a pharmaceutical company focused on discovering and developing pathway-selective drugs that target G-protein coupled receptors (GPCRs). Founded in 2015 and based in Philadelphia, Pennsylvania, Mebias aims to create next-generation GPCR drugs that minimize on-target side effects traditionally associated with these therapies. The company utilizes a validated drug discovery platform to identify molecules that can selectively bind to GPCRs, which may lead to improved treatment options for a range of conditions, including neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular diseases, and immuno-oncology. By employing this innovative approach, Mebias Discovery seeks to reduce the risks commonly associated with conventional drug development methods, thus providing new therapeutic avenues for various health issues.

Cohero Health offers a proprietary connected health platform for those with respiratory illness. Its sensor-based technology and engaging platform improve medication adherence and care coordination between patients and their care providers. The company offers a suite of tools and technology comprises form flexible inhaler sensors, mobile spirometers, to track real-time adherence and lung function, and a mobile application accessible on iPhone, iWatch, and Android. Cohero Health was founded in 2013 and is headquartered in New York.

Genome Profiling, LLC (www.genprollc.com) is at the forefront of this rapidly emerging market with the first epigenetic biomarker discovery platform that combines a proprietary pre-NGS gDNA preparation kit matched to powerful NGS data analytics algorithms that plug-n-play into standard NGS workflows and enable one NGS run to deliver data for both genomic variant call analyses data AND epigenetic data.

Mebias Discovery, LLC is a pharmaceutical company focused on discovering and developing pathway-selective drugs that target G-protein coupled receptors (GPCRs). Founded in 2015 and based in Philadelphia, Pennsylvania, Mebias aims to create next-generation GPCR drugs that minimize on-target side effects traditionally associated with these therapies. The company utilizes a validated drug discovery platform to identify molecules that can selectively bind to GPCRs, which may lead to improved treatment options for a range of conditions, including neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular diseases, and immuno-oncology. By employing this innovative approach, Mebias Discovery seeks to reduce the risks commonly associated with conventional drug development methods, thus providing new therapeutic avenues for various health issues.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.

Bainbridge Health provides hospital systems with a clinical intelligence and data analytics platform to improve medication safety. It provides hospital safety professionals with an infusion pump management software solution to better manage pump data and enhance patient safety. Bainbridge Health also offers a clinician-focused infusion pump management system known as InfusionWare that enables clinicians to manage infusion data in one centralized location.

Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.

Olive Devices is an assistive device company developing smart glasses to improve communication for deaf and hard of hearing persons.

Penn State Health is a multi-hospital health system that serves patients and communities across Central Pennsylvania. It includes the Milton S. Hershey Medical Center, a 551-bed Level I regional trauma center recognized for its expertise in complex adult and pediatric cases. As the region's only academic medical center, it is closely affiliated with the Penn State College of Medicine and houses the Children's Hospital at Penn State Health. The medical center has achieved ANCC Magnet Recognition, reflecting its dedication to fostering a supportive professional environment for staff and delivering high-quality patient care.

Cohero Health offers a proprietary connected health platform for those with respiratory illness. Its sensor-based technology and engaging platform improve medication adherence and care coordination between patients and their care providers. The company offers a suite of tools and technology comprises form flexible inhaler sensors, mobile spirometers, to track real-time adherence and lung function, and a mobile application accessible on iPhone, iWatch, and Android. Cohero Health was founded in 2013 and is headquartered in New York.

Noble.MD is a healthcare technology company based in Bryn Mawr, Pennsylvania, founded in 2012. The company develops Theo, a digital healthcare advisory platform designed to assist patients in identifying health and behavioral risks. The platform actively engages patients by providing programs and interventions to help them manage these risks. By capturing essential patient data at the time of care, Noble.MD facilitates value-based reimbursement and aligns the interests of providers and payers, enhancing the processes of risk identification, coding, and management.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.

Oncora Medical, Inc. is a digital health company focused on enhancing radiation oncology through an innovative analytics platform. Founded in 2014 and based in Philadelphia, Pennsylvania, the company provides tools that facilitate the integration of clinical data from electronic medical records, treatment planning software, and oncology information systems. This allows radiation oncologists to make personalized treatment recommendations based on historical data and predictive analytics. The platform also employs machine learning algorithms to analyze patient outcomes, enabling oncologists to improve cancer care and optimize treatment strategies. By leveraging real-world data, Oncora Medical aims to support better healthcare decisions and ultimately enhance patient outcomes in radiation oncology.

Mebias Discovery, LLC is a pharmaceutical company focused on discovering and developing pathway-selective drugs that target G-protein coupled receptors (GPCRs). Founded in 2015 and based in Philadelphia, Pennsylvania, Mebias aims to create next-generation GPCR drugs that minimize on-target side effects traditionally associated with these therapies. The company utilizes a validated drug discovery platform to identify molecules that can selectively bind to GPCRs, which may lead to improved treatment options for a range of conditions, including neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular diseases, and immuno-oncology. By employing this innovative approach, Mebias Discovery seeks to reduce the risks commonly associated with conventional drug development methods, thus providing new therapeutic avenues for various health issues.

Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.

RiboNova Inc. is a biopharmaceutical company based in Wynnewood, Pennsylvania, focused on developing small molecule drugs aimed at treating serious rare diseases, including certain cancers and mitochondrial diseases. Incorporated in 2011, RiboNova leverages a drug discovery platform that targets defective transfer RNA molecules, which play a critical role in cellular function. The company's innovative approach centers on precision medicines that address ribonucleic acid anomalies, providing healthcare professionals with new treatment options for patients suffering from genetically confirmed mitochondrial conditions and select cancer types. RiboNova operates within the Lankenau Institute for Medical Research near Philadelphia, emphasizing its commitment to advancing therapeutic solutions in the field of rare diseases.

Hsiri Therapeutics, LLC is a development stage pharmaceutical company focused on creating new antibiotics to combat serious infectious diseases caused by drug-resistant bacteria. The company targets two primary groups of pathogens: mycobacterial diseases and gram-negative infections. Notably, it is developing treatments for methicillin-resistant Staphylococcus aureus, drug-resistant Mycobacterium tuberculosis, and infections caused by Mycobacterium avium intracellulare and Pseudomonas aeruginosa, particularly in hospitalized patients. Hsiri's product pipeline includes HT-01, a topical compound for gram-positive infections; HT-02, for serious gram-positive infections; HT-03, an anti-mycobacterial agent; HT-04, for drug-resistant Mycobacterium tuberculosis; and HT-05, which features novel modifications of the standard amino-penicillin framework. The company also explores therapies for Acinetobacter and Klebsiella infections. Founded in 2012 and based in Media, Pennsylvania, Hsiri Therapeutics evolved from antibiotic research initiated by Professor Marvin Miller at the University of Notre Dame.

Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.

CarePartners Plus, LLC is a technology-driven healthcare communications and data company based in Horsham, Pennsylvania. Established in 2009, it specializes in providing patient management solutions through its Wellby platform, a cloud-based system that enhances patient engagement and care coordination. The platform captures and analyzes patient-generated information in real time, facilitating better healthcare experiences and outcomes. CarePartners Plus serves a diverse range of clients, including pharmaceutical companies, health insurers, hospitals, medical groups, employers, government agencies, and educators. By focusing on patient-centric approaches, the company aims to transform healthcare delivery and align stakeholder incentives towards improved compliance and satisfaction.

Allevi develops innovative tools for designing and engineering 3D tissues, focusing on bioprinting technology. The company offers desktop 3D bioprinters that allow users to create functional three-dimensional living tissues using various biomaterials and cell lines. Additionally, Allevi provides bioinks made from collagen and hyaluronic acid, which are available for purchase online. Their cloud-based platform, Bioprint Online, enables users to design complex structures, define materials, and monitor the printing process. Allevi's products serve a diverse clientele, including researchers in tissue engineering, regenerative medicine, and cell biology, as well as industrial and pharmaceutical companies for drug testing and development, and educators. Established in 2014 and based in Philadelphia, Pennsylvania, Allevi was formerly known as BioBots, Inc.

WellTrackONE is a population health management company that offers an end-to-end solution to physician offices, ACOs, integrated delivery networks, hospitals, and other physician networks that helps them administer the Medicare Annual Wellness Visit to all their Medicare patients. The company provides clinical risk management services used to offer a comprehensive baseline report for detailing modifiable risk factors, preventative goals, and measurable data. It was founded in 2012 and headquartered in Hilton Head Island, South Carolina.

Galleon Pharmaceuticals, Inc. is a pharmaceutical company based in Horsham, Pennsylvania, founded in 2003. It specializes in discovering and developing treatments for sleep apnea and related breathing control disorders. The company has a portfolio of therapeutics, including GAL-021, a small molecule administered intravenously to support respiratory drive in surgical and critical care patients, and GLN-21,160, an oral candidate aimed at treating sleep apnea. Additionally, Galleon is developing GAL-044, a small molecule designed to prevent surgical pain. The company's focus extends to addressing conditions such as ventilator weaning, anesthetic-induced respiratory depression, chronic obstructive pulmonary disease (COPD), and obesity-hypoventilation syndrome, with the goal of improving respiratory health for patients.

Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.

HealthQX specializes in Value-based Payment (VBP) analytic software solutions for health plans and providers. Its VBP analytics platform, ClarityQx, provides the capabilities to design, implement, and monitor the on-going performance of payment models such as episodic, bundled, or accountable care arrangements. The company was founded in 2012 and is based in King Of Prussia, Pennsylvania.

TowerView helps the 1 in 3 Americans with a chronic illness manage multiple medications. TowerView’s patients receive pre-filled medication trays that fit into a connected pillbox like a K-Cup into a Keurig coffee machine. Their pillbox can sense when patients forget a dose and automatically sends a text or phone reminder. Unlike other smart pillboxes, they send patients pre-filled medication trays sourced from a pharmacy so patients never have to fill their own pillbox and they work directly with nurses​ to target outreach for non-adherent patients. TowerView is rolling out with Independence Blue Cross in January 2015 and are in advanced discussions with numerous other health plans.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.

Merganser Biotech, Inc. is a research and development company focused on creating innovative medicines for the treatment of rare hematological and iron overload diseases, such as hemochromatosis, polycythemia vera, acute severe infections, and beta thalassemia. The company specializes in the development of hepcidin mimetic peptides, which are designed to regulate iron metabolism and address ineffective erythropoiesis. Founded in 2011, Merganser Biotech is headquartered in King of Prussia, Pennsylvania.

Hsiri Therapeutics, LLC is a development stage pharmaceutical company focused on creating new antibiotics to combat serious infectious diseases caused by drug-resistant bacteria. The company targets two primary groups of pathogens: mycobacterial diseases and gram-negative infections. Notably, it is developing treatments for methicillin-resistant Staphylococcus aureus, drug-resistant Mycobacterium tuberculosis, and infections caused by Mycobacterium avium intracellulare and Pseudomonas aeruginosa, particularly in hospitalized patients. Hsiri's product pipeline includes HT-01, a topical compound for gram-positive infections; HT-02, for serious gram-positive infections; HT-03, an anti-mycobacterial agent; HT-04, for drug-resistant Mycobacterium tuberculosis; and HT-05, which features novel modifications of the standard amino-penicillin framework. The company also explores therapies for Acinetobacter and Klebsiella infections. Founded in 2012 and based in Media, Pennsylvania, Hsiri Therapeutics evolved from antibiotic research initiated by Professor Marvin Miller at the University of Notre Dame.

Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.

OSSIANIX is a privately held biotherapeutics company that develops single domain antibodies based on the highly versatile VNAR structure from shark. Due to remarkable biological and biophysical properties, the VNAR platform can rapidly deliver unique, exquisitely high-affinity products to multiple target classes and overcomes most disadvantages of conventional monoclonal antibody therapy. The platform is also ideal for generating bispecific and trispecific products that can be engineered with ease to develop products with differentiated features in clinically meaningful conditions and also allow targeting to both the blood brain barrier and GI tract for CNS and oral applications.

Immunome Inc. is a biotechnology company based in Exton, Pennsylvania, specializing in the discovery and development of human cancer antibodies that target universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that effectively target these antigens. Additionally, Immunome employs its ScreenMab technology for multiplex functional screening, which focuses on monoclonal antibodies with high specificity for tumor neoantigens. Founded in 2006, Immunome is dedicated to advancing immunotherapy through its innovative approaches in antigen discovery and antibody development.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York, focused on developing innovative treatments for central nervous system (CNS) diseases. The company is advancing its lead product candidate, d-Methadone (also known as esmethadone or REL-1017), a novel NMDA receptor antagonist currently in late-stage development as an adjunctive treatment for major depressive disorder in adults. Additionally, Relmada is working on several other drug formulations, including LevoCap ER, an abuse-resistant sustained-release version of levorphanol; BuTab, an oral formulation of buprenorphine; and MepiGel, a topical formulation of the local anesthetic mepivacaine, which has received orphan drug designation. Founded in 2004, Relmada Therapeutics aims to address significant unmet medical needs in the treatment of CNS disorders.

Halo Labs is a life science instrumentation company based in Burlingame, California, that specializes in developing tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technology. Its offerings include tools for biologics-developability assessment, formulation development, small molecule solubility, and AAV analytics. Founded in 2011, Halo Labs has gained recognition in the industry, receiving support from notable investors and partners such as BioAdvance and the National Science Foundation. The company aims to provide researchers with accurate insights into the stability and quality of biological drugs.

BioDetego is focused on advancing cancer treatment through its innovative biomarker test, VASPfore, which is designed to optimize the selection of chemotherapy protocols. This test assesses the metastatic risk in colorectal cancer patients, allowing healthcare providers to identify high-risk individuals who are likely to benefit from chemotherapy while sparing low-risk patients from unnecessary and potentially harmful treatments. By providing actionable insights, VASPfore aims to improve patient outcomes and enhance the efficiency of cancer management. BioDetego anticipates significant cost savings for payors, estimating reductions of over $150 million annually in treatment expenses. The company is led by David Zuzga, Ph.D., and Giovanni M. Pitari, M.D., Ph.D., both of whom bring extensive expertise in cell and molecular biology and translational oncology, respectively.

HealthQX specializes in Value-based Payment (VBP) analytic software solutions for health plans and providers. Its VBP analytics platform, ClarityQx, provides the capabilities to design, implement, and monitor the on-going performance of payment models such as episodic, bundled, or accountable care arrangements. The company was founded in 2012 and is based in King Of Prussia, Pennsylvania.

InfraScan is a medical device company that invented and distributes hand-held diagnostic devices for head injury and stroke assessment based on Near-Infrared (NIR) technology. The Infrascanner enables clinicians to effectively, conveniently, and accurately detect intracranial bleeding in patients with head trauma. Intracranial hematomas are an important and, if diagnosed early, treatable cause of secondary brain injury in patients with head trauma. Recent statistics from Iraq shows that 30% of all wounded in action have head injuries, and 40% of them have brain hematomas. Dr. Britton Chance (University of Pennsylvania) and Dr. Claudia Robertson (Baylor College of Medicine) invented a NIR system for detection of brain hematomas and tested it successfully in 305 patients in Baylor. An entrepreneurial team formed a company around this technology in collaboration with Drexel University and won the Wharton Business Plan competition in April 2004 and the second prize at the global business plan competition in Singapore in October 2004. The Office of Naval Research funded the company in May, the Biotechnology Greenhouse of Southeastern Pennsylvania, from Ben Franklin Technology Partners of Southeastern Pennsylvania, and from Philadelphia Industrial Development Corporation. A multi-center clinical study to support an FDA submission started in July 2006, and on February 2008 an application was submitted to the FDA.

Merganser Biotech, Inc. is a research and development company focused on creating innovative medicines for the treatment of rare hematological and iron overload diseases, such as hemochromatosis, polycythemia vera, acute severe infections, and beta thalassemia. The company specializes in the development of hepcidin mimetic peptides, which are designed to regulate iron metabolism and address ineffective erythropoiesis. Founded in 2011, Merganser Biotech is headquartered in King of Prussia, Pennsylvania.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. Founded in 2010 and based in Malvern, Pennsylvania, the company specializes in developing antibacterial drugs to combat resistant infections commonly encountered in hospital and community settings, such as those caused by MRSA, Pseudomonas spp., and Salmonella spp. Venatorx employs innovative chemical approaches to create treatments that exhibit selective and potent activity against various resistant bacterial strains, thereby providing healthcare professionals with broader treatment options to address significant unmet medical needs.

Immunome Inc. is a biotechnology company based in Exton, Pennsylvania, specializing in the discovery and development of human cancer antibodies that target universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that effectively target these antigens. Additionally, Immunome employs its ScreenMab technology for multiplex functional screening, which focuses on monoclonal antibodies with high specificity for tumor neoantigens. Founded in 2006, Immunome is dedicated to advancing immunotherapy through its innovative approaches in antigen discovery and antibody development.

Halo Labs is a life science instrumentation company based in Burlingame, California, that specializes in developing tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technology. Its offerings include tools for biologics-developability assessment, formulation development, small molecule solubility, and AAV analytics. Founded in 2011, Halo Labs has gained recognition in the industry, receiving support from notable investors and partners such as BioAdvance and the National Science Foundation. The company aims to provide researchers with accurate insights into the stability and quality of biological drugs.

Microbiota is spun out from university of Pennsylvania, to develop a gut microbiome-based treatment for hyperammonemia.

Annovis Bio, Inc. is a clinical-stage pharmaceutical company based in Berwyn, Pennsylvania, specializing in the development of treatments for neurodegenerative disorders, particularly Alzheimer's disease and Parkinson's disease. The company is advancing several compounds in clinical trials, with its lead candidate, ANVS401, currently in Phase 2a trials aimed at treating Alzheimer’s disease, Parkinson’s disease, and other chronic neurodegenerative conditions. Additionally, Annovis is developing ANVS405, which focuses on providing neuroprotection following traumatic brain injuries and strokes, and ANVS301, which is in Phase I trials designed to enhance cognitive function in later stages of Alzheimer’s disease and dementia. Founded in 2008, Annovis Bio is dedicated to creating innovative therapies to address the challenges posed by these debilitating diseases.

OSSIANIX is a privately held biotherapeutics company that develops single domain antibodies based on the highly versatile VNAR structure from shark. Due to remarkable biological and biophysical properties, the VNAR platform can rapidly deliver unique, exquisitely high-affinity products to multiple target classes and overcomes most disadvantages of conventional monoclonal antibody therapy. The platform is also ideal for generating bispecific and trispecific products that can be engineered with ease to develop products with differentiated features in clinically meaningful conditions and also allow targeting to both the blood brain barrier and GI tract for CNS and oral applications.

Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.

Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.

Immunome Inc. is a biotechnology company based in Exton, Pennsylvania, specializing in the discovery and development of human cancer antibodies that target universal cancer antigens. The company utilizes its proprietary RealMAb technology to identify novel antigens and the corresponding native human antibodies that effectively target these antigens. Additionally, Immunome employs its ScreenMab technology for multiplex functional screening, which focuses on monoclonal antibodies with high specificity for tumor neoantigens. Founded in 2006, Immunome is dedicated to advancing immunotherapy through its innovative approaches in antigen discovery and antibody development.

Life Mist Technologies, Inc., based in Paoli, Pennsylvania, specializes in developing and commercializing an innovative atomization technology that generates a high volume of micron-sized droplets using low-pressure gas and liquid. This technology is designed for a diverse array of industrial applications, including aircraft fire suppression, chemical processing, emission control, turbine inlet cooling, and decontamination. Additionally, it serves sectors such as artificial snow production and cooling systems. By leveraging its unique atomization capabilities, Life Mist Technologies aims to enhance existing processes and provide effective solutions to various industrial challenges. The company has been operational since its incorporation in 2004.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing small molecule drugs and therapeutics aimed at treating various chronic diseases. Established in 2004, the company specializes in creating peripherally selective agents for conditions such as diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), obesity, autoimmune and inflammatory disorders, and malaria. By targeting peripheral tissues, Jenrin Discovery aims to enhance treatment options for physicians and improve patient outcomes in these therapeutic areas.

Niiki Pharma is a development-focused oncology company that specializes in creating first-in-class cancer treatments aimed at novel cellular targets, along with related companion diagnostics. The company is committed to advancing innovative therapies to improve cancer care, leveraging a team of experts in cancer drug development and commercialization. Niiki Pharma emphasizes quality, speed, and capital efficiency in its programs, positioning itself as a key player in the oncology sector.

Innovative Supply Solutions LLC is a specialty contract service organization based in Southampton, Pennsylvania, focused on clinical drug supply chain management. The company offers a comprehensive range of services, including planning and forecasting for active pharmaceutical ingredients and formulated products, project and budget management, inventory oversight, and supply chain coordination. Additionally, it provides support in manufacturing, packaging design, labeling, distribution, and consultancy. Innovative Supply Solutions has developed proprietary software that enhances the efficiency and effectiveness of supply chain management by facilitating coordination and reducing risks associated with clinical trials. This technology has been in use since 2010, delivering accurate forecast results with variances of less than 10%. The company aims to support healthcare providers by lowering costs and improving the overall management of clinical drug supplies.

Anakim Biologics is developing efficiencies and improvements in biologics manufacturing.

Treventis Corporation specializes in developing small molecule drugs aimed at treating and preventing protein misfolding diseases, particularly focusing on tauopathies related to Alzheimer’s disease. The company employs a proprietary discovery engine called Common Conformational Morphology (CCM), which integrates advanced in silico modeling with extensive expertise in drug development across various biological systems. This innovative approach allows Treventis to identify druggable active sites in misfolded protein targets, facilitating the rational design of therapeutic compounds. The lead program is centered around anti-misfolding small molecules that target tau proteins, while additional CCM-driven initiatives are underway in oncology and other neurodegenerative disorders, highlighting the versatility of their technology platform. The drugs developed by Treventis aim to effectively neutralize misfolded proteins, potentially blocking the progression of amyloid toxicity and offering a treatment option for Alzheimer’s patients with minimal side effects.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York, focused on developing innovative treatments for central nervous system (CNS) diseases. The company is advancing its lead product candidate, d-Methadone (also known as esmethadone or REL-1017), a novel NMDA receptor antagonist currently in late-stage development as an adjunctive treatment for major depressive disorder in adults. Additionally, Relmada is working on several other drug formulations, including LevoCap ER, an abuse-resistant sustained-release version of levorphanol; BuTab, an oral formulation of buprenorphine; and MepiGel, a topical formulation of the local anesthetic mepivacaine, which has received orphan drug designation. Founded in 2004, Relmada Therapeutics aims to address significant unmet medical needs in the treatment of CNS disorders.

Innovative Supply Solutions LLC is a specialty contract service organization based in Southampton, Pennsylvania, focused on clinical drug supply chain management. The company offers a comprehensive range of services, including planning and forecasting for active pharmaceutical ingredients and formulated products, project and budget management, inventory oversight, and supply chain coordination. Additionally, it provides support in manufacturing, packaging design, labeling, distribution, and consultancy. Innovative Supply Solutions has developed proprietary software that enhances the efficiency and effectiveness of supply chain management by facilitating coordination and reducing risks associated with clinical trials. This technology has been in use since 2010, delivering accurate forecast results with variances of less than 10%. The company aims to support healthcare providers by lowering costs and improving the overall management of clinical drug supplies.

Halo Labs is a life science instrumentation company based in Burlingame, California, that specializes in developing tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technology. Its offerings include tools for biologics-developability assessment, formulation development, small molecule solubility, and AAV analytics. Founded in 2011, Halo Labs has gained recognition in the industry, receiving support from notable investors and partners such as BioAdvance and the National Science Foundation. The company aims to provide researchers with accurate insights into the stability and quality of biological drugs.

Melior Discovery, Inc. is a biotechnology company that specializes in identifying novel therapeutic applications for existing drugs through its in vivo pharmacology platform. Founded in 2005 and based in Exton, Pennsylvania, Melior utilizes its theraTRACE indications discovery platform to systematically evaluate compounds across multiple validated in vivo models. This approach allows the company to explore potential therapeutic uses in various areas, including neurodegenerative diseases, psychiatry, inflammation, pain management, metabolic disorders, gastrointestinal and urology, cardiovascular diseases, and dermatology. By offering rapid and cost-effective screening solutions, Melior Discovery serves clients in the pharmaceutical and biopharmaceutical industries, assisting them in uncovering new indications for pre-clinical and development-stage drug candidates.

Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing a proprietary gel formulation of mechlorethamine hydrochloride for treating early-stage (stages I-IIA) mycosis fungoides, a form of Cutaneous T-Cell Lymphoma (CTCL). If approved, this investigational drug would be the first topical mechlorethamine product available for managing the signs and symptoms of this rare cancer. In addition to this primary focus, Ceptaris is also involved in developing other therapeutic products, including YT-1006, an NMDA antagonist aimed at treating neuropathic pain while minimizing side effects associated with NMDA. The company's innovative approaches enable healthcare professionals to address both dermatological and central nervous system disorders effectively.

COOL~BIO is a biotechnology company focused on developing hypothermia-activated biologics. Therapeutic hypothermia (TH) is the process of cooling the body to prevent organ damage and is widely-used in cardiac surgery, ischemic stroke, cardiac arrest, neurosurgery and traumatic brain injury. Their lead molecule is an anti-platelet agent being developed for use during cardiopulmonary bypass.

CarePartners Plus, LLC is a technology-driven healthcare communications and data company based in Horsham, Pennsylvania. Established in 2009, it specializes in providing patient management solutions through its Wellby platform, a cloud-based system that enhances patient engagement and care coordination. The platform captures and analyzes patient-generated information in real time, facilitating better healthcare experiences and outcomes. CarePartners Plus serves a diverse range of clients, including pharmaceutical companies, health insurers, hospitals, medical groups, employers, government agencies, and educators. By focusing on patient-centric approaches, the company aims to transform healthcare delivery and align stakeholder incentives towards improved compliance and satisfaction.